Patients without ovarian cancer were excluded from retrospective analysis of details of hypersensitivity reactions recorded contemperaneously between April 2019 - January 2020 on excel and chemocare (CIS Oncology, Belfast, UK) by the treating practitioner. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. van de Loosdrecht, Arjan A. Efficacy and Adverse Events of Carboplatin Desensitisation Therapy for Gynaecological Cancer: A Retrospective Study. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Ann Oncol. Europes Beating Cancer Plan in 60 minutes, World Cancer Report Updates Learning Platform, ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), Recognition and Status of Medical Oncology, Status of Medical Oncology in Developing Countries, Shortages of Inexpensive, Essential Cancer Medicines, Accessibility and Availability of Medicines, Availability and Accessibility of Biomolecular Technologies in Oncology, CAREFOR, The Clinical Academic Cancer Research Forum, World Health Organization / United Nations, ESMO responses to European Union and Global Public Consultations, ESMO Facebook Roundtable: COVID-19 Vaccines and Cancer Care - The known, the unknown and the unknowable, ESMO Facebook Roundtable: COVID-19 vs Cancer - Reorganising cancer care after the first wave, ESMO Facebook Roundtable: COVID-19 vs Cancer - The future of cancer research, ESMO Facebook Roundtable: COVID-19 vs Cancer - Weighing up risks over time, COVID-19 and cancer care in the ESMO journals. Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines (2017) 8 Pager Instructions Coverage Begins March 1, 2019 Coverage Ends: TBD 1. . Cancer Sci. WHIPPANY, N.J., Sept. 1, 2017 /PRNewswire/ -- Bayer will present the latest research from across its growing oncology portfolio at the European Society for Medical Oncology (ESMO) 2017 Congress . ESMO Clinical Practice Guideline update on the use of systemic therapy Paclitaxel plus platinum-based chemotherapy vs. conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. The symptoms and signs of the 75 women with carboplatin-related hypersensitivity reactions are given in Table 4. Among the 651 women (88.6%) diagnosed with ovarian cancer, 474 (64.5%) had stage IIIIV disease. de Las Vecillas Snchez L, Alenazy LA, Garcia-Neuer M, Castells MC. Among cases developing carboplatin-related hypersensitivity reactions, the median number of cycles is 912, and the median doses 6,0008,000 mg. Reported risk factors for carboplatin-related hypersensitivity reactions include carboplatin cycle/dose, platinum-free interval, and history of drug allergies (Libra et al., 2003; Confino-Cohen et al., 2005; Schwartz et al., 2007; Koshiba et al., 2009). 2018 Oct 1;29(Suppl 4):iv260. (2009) reported a 3.54% rate of severe carboplatin-related hypersensitivity reactions, which is similar to our rate of 2.2%. Drug Interactions in the Treatment of Malignancy in HIV-Infected Patients. A sincere thanks to the almost 24,000 participants who attended this year's annual congress! Most events occurred during chemotherapy. HHS Vulnerability Disclosure, Help Management of uncommon chemotherapy-induced emergencies. Clipboard, Search History, and several other advanced features are temporarily unavailable. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. In an era of deep understanding of the molecular biology underlying the development of cancer, it is crucial that researchers and clinicians exchange knowledge. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). Zweizig, S., Roman, L. D., and Muderspach, L. I. Educate. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. and transmitted securely. Libra, M., Sorio, R., Buonadonna, A., Berretta, M., Stefanovski, P., Toffoli, G., et al. Study conception and design: Y-HT and W-FC. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. Esmo | Esmo Oncol Res Treat. Analysis and interpretation of data: Y-HT, Y-JT, H-CH, Y-YC, and W-FC. 21, 31943200. doi: 10.1111/IGC.0b013e3181a1bf2e, Ledermann, J. doi: 10.1200/JCO.1999.17.4.1141, Moon, D. H., Lee, J. M., Noonan, A. M., Annunziata, C. M., Minasian, L., Houston, N., et al. Authorship includes a multidisciplinary group of experts from different institutions and countries in Europe and abroad. Supportive and Palliative Care | ESMO Management of Infusion Reactions to Systemic Anticancer Therapy: ESMO Clinical Practice Guidelines Published in 2017 - Ann Oncol (2017) 28 (suppl 4): iv100-iv118. Virtually all chemotherapeutic agents have the potential to initiate infusion reactions, defined in this review as unexpected reactions that cannot be explained by the known toxicity profile of the drug. Markman et al. All of these reported symptoms and signs occurred within an hour of initiating carboplatin administration. These recommendations aim to develop guidance to mitigate the negative effects of the COVID-19 pandemic on the diagnosis and treatment of cancer patients. (Moon et al., 2013) BRCA1/2 mutation patients had early-onset carboplatin hypersensitivity at a lower cumulative exposure. are hypersensitivity reactions that are systemic and can be life-threatening (Olsen et al., 2019; Rosell et al., 2017). Oncol. Management of Infusion Reactions to Systemic Anticancer Therapy: ESMO Clinical Practice Guidelines, Adolescents and Young Adults Working Group, ESMO SIOG Cancer in the Elderly Working Group, Examination & Accreditation Working Group, Real World Data and Digital Health Working Group, Translational Research and Precision Medicine Working Group, ESMO-Magnitude of Clinical Benefit Scale Working Group, Press and Media Affairs Committee and Social Media Working Group, ESMO-MCBS Working Group: Open Call for New Extended Members, ESMO Co-Editors-in-Chief for ESMO Journals Open Call for Members, ESMO Clinical Research Observatory Task Force (ECRO), Notification of 2022 ESMO General Assembly Vote, EnLiST ESMO Adaptation of Line of Systemic Therapy, Cancer Patient Management During the COVID-19 Pandemic, Primary brain tumours in the COVID-19 era, Gastrointestinal cancers: Hepatocellular carcinoma (HCC) in the COVID-19 era, Genitourinary cancers: Urothelial cancer of the bladder in the COVID-19 era, Genitourinary cancers: Renal cell cancer in the COVID-19 era, Genitourinary cancers: Prostate cancer in the COVID-19 era, Gynaecological malignancies: Cervical cancer in the COVID-19 era, Gynaecological malignancies: Endometrial cancer in the COVID-19 era, Haematological malignancies: DLBCL, MCL and Aggressive T-cell lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Hodgkin lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Indolent B-NHL in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Multiple myeloma in the COVID-19 era, Head and neck cancers in the COVID-19 era, COVID-19 adapted recommendations Slide Sets, ESMO Courses on Medical Oncology for Medical Students, External Oncology Fellowship Opportunities, ESMO Resilience Task Force: Survey Series, ESMO-MORA Recertification Process and Requirements, ESMO Certificate of Professional Development, Professor of Cancer Research and Tony Charlton Chair, Monash University, Melbourne, Australia, Acknowledgements: Rationalizing Bureaucracy, Bibliography on Clinical Trial Procedures, ESMO Designated Centres of Integrated Oncology & Palliative Care, Palliative and Supportive Care Sessions at ESMO Congress 2022 Paris, Krebstherapie whrend der COVID-19-Pandemie, Traitement du Cancer au Cours de la Pandmie de COVID-19, Le Cure per il Cancro Durante la Pandemia da COVID-19, Cuidado del cncer durante la pandemia de COVID-19, Access to Cancer Medicines and Technologies, ESMOs Mission on Access to Cancer Medicines and Technologies, ESMO Public Policy Track and Special Sessions. MINIMAL Requirements:Google Chrome 24+,Mozilla Firefox 20+,Internet Explorer 11,Opera 1518,Apple Safari 7,SeaMonkey 2.15-2.23, Published in 2017 Ann Oncol (2017) 28 (suppl 4): iv100iv118.Authors: S. Rosell, I. Blasco, L. Garca Fabregat, A. Cervantes and K. Jordan. 2019 Sep;60(9):2295-2298. doi: 10.1080/10428194.2019.1576871. The https:// ensures that you are connecting to the See this image and copyright information in PMC. Note: Approved by the ESMO Guidelines Committee: July 2017, last update October 2022. . Upon the occurrence of symptoms and signs, carboplatin infusion was immediately stopped. Int. 107, 163165. Altwerger et al. (2003). Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase1 Study of Intravenous Fosnetupitant. Before doi: 10.1093/annonc/mdx216. Guidelines | ESMO A., Colombo, N., du Bois, A., Delaloye, J. F., Kristensen, G. B., et al. (PDF) Management of cancer pain in adult patients: ESMO Clinical Carboplatin rechallenge after hypersensitivity reactions in pediatric patients with low-grade glioma. In our study, 36% of the patients with carboplatin-related hypersensitivity reactions had a history of drug allergies. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel on patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. (2005) reported that all carboplatin-associated hypersensitivity reactions occur in patients with prior carboplatin exposure, and Tamiya et al. Genc et al. 2017;40(3):120-127. doi: 10.1159/000458443. J. Clin. ESMO Virtual Congress 2020 | OncologyPRO By delivering the target dose of the drug by small incremental doubling doses (Figure 3), the threshold for anaphylaxis is re-established at each step and never reaches that of the initial triggering dose. Front Oncol. Multivariate analyses of clinical parameters for carboplatin-related hypersensitivity reactions. 1; Mandac Smoljanovi, Inga 2. For more detailed information on the cookies we use, please check our Privacy Policy. Ovarian cancer is the leading cause of death from gynecological malignancies (Chiang et al., 2013), with a 5-year survival rate of 46% in the United States (92% when localized, 73% with regional metastases, and 28% with distant metastases) (Siegel et al., 2016). . Would you like email updates of new search results? EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Myelodysplastic Syndromes. PDF | On Jul 1, 2017, J B A G Haanen and others published Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Find, read and . Atopic patients are at increased risk for chemotherapy and MoAbs drug allergy and the current patterns of treatment with recurrent and intermittent drug exposures may favor the development of drug allergies. Author Information. doi: 10.1006/gyno.2001.6519, Gadducci, A., Tana, R., Teti, G., Zanca, G., Fanucchi, A., and Genazzani, A. R. (2008). There is a need to further characterise risk of anaphylaxis/hypersensitivity with PH IV/PH FDC SC to support safe administration outside of clinics. Read guidelines by topic Latest Guidelines News Drafting of manuscript: Y-HT and W-FC. doi: 10.1200/JOP.18.00761. No use, distribution or reproduction is permitted which does not comply with these terms. One-fifth of these patients never attempt carboplatin reinfusion, even after only mild hypersensitivity reactions (Gadducci et al., 2008). Expert Perspectives: ESMO 2017 Changes Lung Cancer Practice ESMO Colloquia are innovative sessions within the Congress programme, organised by ESMO and supported by industry, Information about the exhibition and Satellite Symposia, Contact details and welcome message, plus other general information about ESMO 2017. FOIA A framework to rank genomic alterations as targets for cancer precision medicine.ESCAT scores for genomic alterations with actionable drug matches are now being gradually integrated into ESMO tumour-focused Clinical Practice Guidelines. It didn't disappoint. (2016). J. Create your own personalised agenda and browse the complete scientific programme by day, topic, cancer type and track with the ESMO events app. Oncol. PH IV/PH FDC SC is standard of care for HER2-positive BC and usually given with chemotherapy, all of which can trigger anaphylaxis/hypersensitivity. This site uses cookies. The cumulative incidence of carboplatin-related hypersensitivity was 2% at >3,500 mg, 6% at >7,500 mg, 8% at >10,000 mg, and 10% at >16,000 mg with a plateau beyond this dose (Figure 1B). We evaluated the prevalence of and risk factors for hypersensitivity reactions related to carboplatin, which is commonly used to treat gynecological malignancies. During the study period, our institution applied carboplatin (including carboplatin with cyclophosphamide or paclitaxel) as the front-line chemotherapy for women with ovarian, fallopian tube, and primary peritoneal cancer. ESMO on Anemia, Iron Deficiency in Cancer Patients ESMO Call to Action on COVID-19 Vaccinations and Patients with Cancer: Vaccinate. Risk Factors of Hypersensitivity to Carboplatin in Patients with Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K; ESMO Guidelines Committee. Median cycle and dose of carboplatin administered to women with or without hypersensitivity reactions. 84, 378382. Abe, A., Ikawa, H., and Ikawa, S. (2010). 2017 Nov 8;8:1472. doi: 10.3389/fimmu.2017.01472. Utilizing Biologics in Drug Desensitization. Bayer to Highlight New Research at ESMO 2017 Congress - PR Newswire For more detailed information on the cookies we use, please check our Privacy Policy. Adnan A, Acharya S, Alenazy LA, de Las Vecillas L, Giavina Bianchi P, Picard M, Calbache-Gil L, Romero-Pinedo S, Abad A-Molina AC, Kerr W, Pedicone C, Nagai J, Hollers E, Dwyer D, Castells M. J Immunol. A total of 412 (56.1%) patients experienced spontaneous menopause, 295 (40.1%) surgical menopause, and 28 (3.8%) had preserved fertility. In the majority of ovarian cancer cases, primary management entails surgical staging or cytoreduction, followed by systemic chemotherapy (Ledermann et al., 2013). LUGANO-MADRID, 09 September, 2017 -The preliminary results of a study to be presented at the ESMO 2017 Congress in Madrid (1) show that socio-psychological factors have become more significant for . An official website of the United States government. Severe reactions are less frequent and may be fatal without appropriate intervention. MBC: CLEOPATRA (NCT00567190; PMID 22149875, 23602601, 25693012; 32171426), MetaPHER (NCT02402712; 33748921); EBC: APHINITY (NCT01358877; 28581356, 33539215), NeoSphere (NCT00545688; 22153890, 27179402), TRYPHAENA (NCT00976989; 23704196, 29223479), BERENICE (NCT02132949; 29253081, SABCS 2017 P5-20-04), FeDeriCa (NCT03493854; 33357420), PHranceSCa (NCT03674112; ESMO 2020 165MO). HemaSphere 6 (3):p e695, March 2022. However, prolonged carboplatin use is associated with an increased incidence of carboplatin-related hypersensitivity reactions (Markman et al., 1999; Wang et al., 2009). Assess for lymphadenopathy, facial or distal extremity swelling (may be signs of drug-induced hypersensitivity syndrome/DRESS). J. Gynecol. This site uses cookies. The ESMO Clinical Practice Guidelines (CPGs) are intended to provide the user with a set of recommendations for the best standards of cancer care, based on the findings of evidence-based medicine. In the present study, 61 patients with carboplatin-related hypersensitivity were rechallenged with carboplatin. Prevention and Management of Dermatological Toxicities Related - ESMO PDF Monoclonal Antibodies This site needs JavaScript to work properly. 28, 33233329. doi: 10.2217/imt.14.71, Chiang, Y. C., Chen, C. A., Chiang, C. J., Hsu, T. H., Lin, M. C., You, S. L., et al. Similarly, Kandel et al. Tx-nave pts ORR was 90%. Morgan C, Tillett T, Braybrooke J, Ajithkumar T. Lancet Oncol. 2011 Aug;12(8):806-14. doi: 10.1016/S1470-2045(10)70208-4. (2009). Management of infusion reactions to systemic anticancer therapy: ESMO This patient developed hypersensitivity reactions during her 23rd cycle of carboplatin administration at a cumulative dose of approximately 14,000 mg. She experienced skin rash, tachycardia, and dyspnea 13 min after starting the infusion. official website and that any information you provide is encrypted Necessary cookies enable core functionality. Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. 4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study. BRCA1/2 mutation has been reported to correlate with carboplatin hypersensitivity (Altwerger et al., 2017). Chemother. Type II hypersensitivity is an IgG or IgM antibody-dependent cytotoxicity in which an antigen attached to cell membranes of red blood cells or platelets binds to an antibody, leading to cell or tissue damage such as haemolytic anaemia or thrombocytopenia. Furthermore, Moon et al. 17 This dose reduction is due to the ability of both aprepitant and netupitant to inhibit the metabolism of dexamethasone leading to higher . Life expectancy for cancer patients allergic and desensitized to carboplatin and non-allergic to carboplatin [from Sloane et al. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Incidence and Management of Olaratumab Infusion-Related Reactions. Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. Model of in vitro mouse mast cells activation and desensitization. Death from anaphylaxis to cisplatin: a case report. 2022 Apr 26;14(4):e24515. The overall safety of desensitization for common chemotherapy drugs and monoclonal antibodies. Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations Front Immunol. The essential content of the guidelinesin condensed slide format in PDF or PowerPoint. Clinical features of hypersensitivity reactions to carboplatin. Via Ginevra 4, 6900 Lugano - CH Copyright 2023 European Society for Medical Oncology All rights reserved worldwide. LBA10004 The full, final text of this abstract will be available at abstracts.asco.org at 2:00 PM (EDT) on Friday, June 2, 2017, and in the Annual Meeting Proceedings online supplement to the June . reactions to foreign proteins [generally immunoglobulin E (IgE)-mediated allergic responses] or non-immune-mediated reactions [1]. Severe carboplatin-related hypersensitivity reactions are uncommon. Evaluating whether any factors can predict carboplatin hypersensitivity, we identified a high correlation with the carboplatin cycle and cumulative dose (Pearson correlation coefficient 0.9318). doi: 10.2152/jmi.57.163, PubMed Abstract | CrossRef Full Text | Google Scholar, Altwerger, G., Gressel, G. M., English, D. P., Nelson, W. K., Carusillo, N., Silasi, D. A., et al. The incidence of carboplatin-related hypersensitivity was higher in patients with advanced stage disease (P < 0.001, Kruskal-Wallis test), serous and mixed histological types (P = 0.003, Kruskal-Wallis test), malignant ascites (P = 0.009, chi-square test), and history of other drug allergy (P < 0.001, chi-square test). Cancer. Oncol. Clinical Practice Guidelines Prevention and Management of Dermatological Toxicities Related to Anticancer Agents, Adolescents and Young Adults Working Group, ESMO SIOG Cancer in the Elderly Working Group, Examination & Accreditation Working Group, Real World Data and Digital Health Working Group, Translational Research and Precision Medicine Working Group, ESMO-Magnitude of Clinical Benefit Scale Working Group, Press and Media Affairs Committee and Social Media Working Group, ESMO-MCBS Working Group: Open Call for New Extended Members, ESMO Co-Editors-in-Chief for ESMO Journals Open Call for Members, ESMO Clinical Research Observatory Task Force (ECRO), Notification of 2022 ESMO General Assembly Vote, EnLiST ESMO Adaptation of Line of Systemic Therapy, Cancer Patient Management During the COVID-19 Pandemic, Primary brain tumours in the COVID-19 era, Gastrointestinal cancers: Hepatocellular carcinoma (HCC) in the COVID-19 era, Genitourinary cancers: Urothelial cancer of the bladder in the COVID-19 era, Genitourinary cancers: Renal cell cancer in the COVID-19 era, Genitourinary cancers: Prostate cancer in the COVID-19 era, Gynaecological malignancies: Cervical cancer in the COVID-19 era, Gynaecological malignancies: Endometrial cancer in the COVID-19 era, Haematological malignancies: DLBCL, MCL and Aggressive T-cell lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Hodgkin lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Indolent B-NHL in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Multiple myeloma in the COVID-19 era, Head and neck cancers in the COVID-19 era, COVID-19 adapted recommendations Slide Sets, ESMO Courses on Medical Oncology for Medical Students, External Oncology Fellowship Opportunities, ESMO Resilience Task Force: Survey Series, ESMO-MORA Recertification Process and Requirements, ESMO Certificate of Professional Development, Professor of Cancer Research and Tony Charlton Chair, Monash University, Melbourne, Australia, Acknowledgements: Rationalizing Bureaucracy, Bibliography on Clinical Trial Procedures, ESMO Designated Centres of Integrated Oncology & Palliative Care, Palliative and Supportive Care Sessions at ESMO Congress 2022 Paris, Krebstherapie whrend der COVID-19-Pandemie, Traitement du Cancer au Cours de la Pandmie de COVID-19, Le Cure per il Cancro Durante la Pandemia da COVID-19, Cuidado del cncer durante la pandemia de COVID-19, Access to Cancer Medicines and Technologies, ESMOs Mission on Access to Cancer Medicines and Technologies, ESMO Public Policy Track and Special Sessions. 2022 May 20;12:879391. doi: 10.3389/fonc.2022.879391. A video magazine about the congress, highlighting the most important information about the event. Monitor. Table 7. *Correspondence: Wen-Fang Cheng, wenfangcheng@yahoo.com, Creative Commons Attribution License (CC BY). Life expectancy for cancer patients allergic and desensitized to carboplatin and non-allergic to, MeSH The site is secure. As shown in Table 6, drug or food history (odd ratios [OR] 2.340, 95% confidence interval [CI] 1.374-3.984, P = 0.0018), malignant ascites (OR 1.895, 95% CI 1.1083.241, P = 0.0196), and cumulative carboplatin dose (4,0004,999 mg: OR 5.507, 95% CI 1.79616.887, P = 0.0028; 5,0009,999 mg: OR 7.244, 95% CI 2.74019.149, P < 0.0001; 10,000 mg: OR 8.461, 95% CI 3.00723.806, P < 0.0001; P for trend < 0.0001) significantly positively correlated with carboplatin hypersensitivity. It would be worthwhile to design a perspective trial that could randomize patients with carboplatin hypersensitivity to receive an alternative regimen without carboplatin. Clipboard, Search History, and several other advanced features are temporarily unavailable. PH IV/PH FDC SC for HER2-positive BC were well tolerated, with few grade 3 anaphylaxis/hypersensitivity events reported with PH IV and no grade 3 related events with PH FDC SC. The incidence of carboplatin hypersensitivity ranges from 8 to 11% (Libra et al., 2003; Confino-Cohen et al., 2005; Schwartz et al., 2007; Koshiba et al., 2009). Unable to load your collection due to an error, Unable to load your delegates due to an error. MINIMAL Requirements:Google Chrome 24+,Mozilla Firefox 20+,Internet Explorer 11,Opera 1518,Apple Safari 7,SeaMonkey 2.15-2.23. government site. 31, 45254528. Patients feel psycho-social impact of chemo m | EurekAlert! Gynecol. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). 4 - 9 Without premedication, hypersensitivity reactions (HSRs) occurred in 25%-30% of patients in these studies and clinical development of paclitaxel was consequently delayed. (2009) reported the successful re-treatment of the majority of patients with previous carboplatin-related hypersensitivity reactions. Int. Oncol. official website and that any information you provide is encrypted Successful carboplatin desensitization in patients with proven carboplatin allergy. Login to your ESMO account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits. National Library of Medicine We found a higher incidence of carboplatin-related hypersensitivity among patients with advanced disease (stage IIIIV) with serous carcinoma and malignant ascites. Front Oncol. MINIMAL Requirements:Google Chrome 24+,Mozilla Firefox 20+,Internet Explorer 11,Opera 1518,Apple Safari 7,SeaMonkey 2.15-2.23. Tamiya, M., Kuhara, H., Hirashima, T., Kondo, Y., Santo, M., Morishita, N., et al. Oncol. Careers. doi: 10.1111/j.1048-891x.2005.14401.x, Takase, N., Matsumoto, K., Onoe, T., Kitao, A., Tanioka, M., Kikukawa, Y., et al.
What Is One Way To Appeal To Pathos Apex,
How To Convince Your Parents After They Say No,
Articles E